Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polycystic Ovarian Syndrome.

8 juin 2026 mis à jour par: Riphah International University

Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Dysmenorrhea, Quality Of Sleep And Stress In Polycystic Ovarian Syndrome.

The study will be a non-blinded randomized controlled trial, consisting of two groups. Non-probability Convenience sampling will be used to recruit participants who will meet the inclusion criteria. Group allocation will be performed using the sealed envelope method to ensure randomization of participants into experimental and control groups. The sample size will be 38 (19 in each group). Group A will receive neurodynamic stretches while Group B will receive myofascial pain release technique.

Aperçu de l'étude

Description détaillée

The most prevalent endocrinopathy in women of reproductive age is polycystic ovarian disorder (PCOS), with notable clinical characteristics related to reproduction, metabolism, dermatology, and psychology. Among the most prominent gynecological disorders in women is dysmenorrhea, which has a major detrimental effect on one's quality of life. This randomized clinical study aims to evaluate and compare the effects of neurodynamic stretching combined with diaphragmatic breathing versus myofascial pain release therapy in reducing the intensity and duration of dysmenorrhea in girls with PCOS, to assess the impact of both interventions on improving the quality of sleep among girls with PCOS and to compare the effects of neurodynamic stretching with diaphragmatic breathing and myofascial pain release therapy on enhancing functional mobility in females with PCOS.

The study will be a non-blinded randomized controlled trial, consisting of two groups. Non-probability Convenience sampling will be used to recruit participants who will meet the inclusion criteria. Group allocation will be performed using the sealed envelope method to ensure randomization of participants into experimental and control groups. The sample size will be 38 (19 in each group). Group A will receive neurodynamic stretches which includes abdominal stretches, calf stretches, hamstring stretches. Group B will receive myofascial pain release technique. The study will be conducted over a period of 10 months at Shaikh Zayed Hospital Lahore. Ethical approval will be obtained. Individuals fulfilling the inclusion criteria will be selected, followed by written informed consent after explaining the study purpose. Participants will then be randomly allocated to one of the two groups. Comparative Training would be performed thrice a week on alternate days for a total duration of 6 weeks. Total sessions will be 18. All outcome measurements will be performed pre and after the 6 weeks' intervention period.

Type d'étude

Interventionnel

Inscription (Estimé)

38

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • Recrutement
        • Shaikh Zayed Hospital
        • Chercheur principal:
          • Azha Farman, MSWHPT

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • • Age 18-35 years

    • Diagnosed cases of PCOS
    • Irregular periods until 3 months.
    • Presence of dysmenorrhea (Check WaLIDD Questionnaire)
    • BMI
    • Age of Menarche (13 years)

Exclusion Criteria:

  • • History of endocrine disorders

    • Endometriosis
    • Tumour
    • Any major surgeries
    • Marital Status (un married)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Neurodynamic stretches
Group A will receive neurodynamic stretches which includes abdominal stretches, calf stretches, hamstring stretches.

Participants will receive neurodynamic mobilization techniques focused on improving the mobility of the lumbosacral plexus and peripheral nerves.

Week 1-2:

  • Introduction to neural sliders only.
  • Techniques: Supine straight leg raise (SLR) with ankle dorsiflexion, femoral nerve glide, and seated slump position.

Frequency: 3 sets of 10 repetitions per nerve. Emphasis: Gentle, pain-free movements with diaphragmatic breathing

Week 3-4:

Progression to sliders + tensioners.

• Techniques: Dynamic slump with tensioning, prone femoral tensioner. Repetitions: 2 sets of 5-7 controlled repetitions. Emphasis: Slight neural load increase while ensuring patient comfort.

Week 5-6:

  • Continuation of advanced techniques with full-range tensioners.
  • Integration of posture correction and relaxation techniques. Emphasis: Endurance and mobility with symptom monitoring. Frequency: 3 sessions per week Duration: 20-30 minutes per session Total duration: 6 weeks
Expérimental: myofascial pain release technique
Group B will receive myofascial pain release technique.

Participants will receive myofascial release therapy aimed at relieving fascial tightness, trigger points, and muscle stiffness in the abdominal, pelvic, and lumbar regions.

Week 1-2:

  • Light pressure applied to abdominal fascia and lower back region.
  • Techniques: Cross-hand fascial release, skin rolling, and gentle pressure on trigger points.

Each hold: 90-120 seconds per site.

Week 3-4:

  • Increased pressure depth depending on patient tolerance.
  • Targeting deeper pelvic structures and sacroiliac area.
  • Use of foam roller introduced for myofascial self-release.

Week 5-6:

  • Maintenance of deeper myofascial techniques with added pelvic stretching.
  • Integration of postural awareness and relaxation breathing.
  • Focus on combining manual release with functional mobility. Frequency: 3 sessions per week Duration: 20-30 minutes per session Total duration: 6 weeks

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mc Gill Questionnaire
Délai: 6 weeks

The short-form McGill Pain Questionnaire (SF-MPQ) is a shorter version of the original MPQ, and was developed later in 1987.The pain rating index has 2 subscales:

  • Sensory subscale with 11 words, and
  • Affective subscale with 4 words from the original MPQ. These words or items are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate and 3 = severe. Version includes 7 additional symptoms related to neuropathic pain, for a total of 22 items with 0-10 numerical response options. The reliability of the tool was measured using Cronbach's alpha value, and it was found to be 0.91
6 weeks
WaLIDD Score
Délai: 6 weeks
The WaLIDD score, or Working ability, Location, Intensity, Days of pain, Dysmenorrhea score, is a tool used to assess and diagnose dysmenorrhea (menstrual cramps) and predict the likelihood of needing medical leave. It's a self-report scale where individuals rate their experience of dysmenorrhea based on four key aspects: pain location, pain range, duration of pain, and disability. The total score, ranging from 0 to 12, categorizes the severity of dysmenorrhea: 0 indicates no dysmenorrhea, 1-4 is mild, 5-7 is moderate, and 8-12 is severe. The reliability of the tool was measured using Cronbach's alpha value, and it was found to be 0.88.
6 weeks
PSQI Scale
Délai: 6 weeks
The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. The reliability of the tool was measured using Cronbach's alpha value, and it was found to be 0.83.
6 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Hafiza Iqra Rubab, MSWHPT, Riphah International University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 octobre 2025

Achèvement primaire (Estimé)

1 juillet 2026

Achèvement de l'étude (Estimé)

1 juillet 2026

Dates d'inscription aux études

Première soumission

8 juin 2026

Première soumission répondant aux critères de contrôle qualité

8 juin 2026

Première publication (Réel)

12 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner